Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Pembrolizumab Solution for Infusion 25mg/mL - HSA Drug Approval Details

Approvals/HSA/Pembrolizumab Solution for Infusion 25mg/mL

Approved

THERAPEUTIC

Pembrolizumab Solution for Infusion 25mg/mL

MSD International GmbH T/A MSD Ireland (Carlow)🇸🇬 Health Sciences Authority

Approval Date: Jan 13, 2023
Approval ID: 47d49360a2fae815
Company: MSD International GmbH T/A MSD Ireland (Carlow)
Type: Therapeutic

Approval Details

Approval Id: 47d49360a2fae815
Drug Name: Pembrolizumab Solution for Infusion 25mg/mL
Product Name: Pembrolizumab Solution for Infusion 25mg/mL
Approval Number: SIN16677P
Approval Date: 2023-01-13
Registrant: MSD PHARMA (SINGAPORE) PTE. LTD.
Licence Holder: MSD PHARMA (SINGAPORE) PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: INFUSION, SOLUTION CONCENTRATE
Route Of Administration: INTRAVENOUS
Atc Code: L01XC18
Atc Item Name: xl 01 xc 18
Pharma Manufacturer Name: MSD PHARMA (SINGAPORE) PTE. LTD.
Company Detail Path: /organization/a411105c4439426e/msd-pharma-singapore-pte-ltd

Active Ingredients

Pembrolizumab

25.0mg/mL

PEMBROLIZUMAB

25 MG/ML

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jan 13, 2023

Approval ID

47d49360a2fae815

Type

Therapeutic

Back to HSA Approvals